293 related articles for article (PubMed ID: 28229824)
21. Subclinical inflammation in a case of menstruation-induced familial Mediterranean fever: A case report.
Hara K; Endo Y; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Migita K; Kawakami A; Koga T
Medicine (Baltimore); 2018 Sep; 97(38):e12305. PubMed ID: 30235678
[TBL] [Abstract][Full Text] [Related]
22. Familial Mediterranean fever (FMF)-response to TNF-blockers used for treatment of FMF patients with concurrent inflammatory diseases.
Haj-Yahia S; Ben-Zvi I; Lidar M; Livneh A
Joint Bone Spine; 2021 Oct; 88(5):105201. PubMed ID: 33932573
[TBL] [Abstract][Full Text] [Related]
23. [INTERLEUKIN 1 INHIBITORS--A NEW HORIZON IN THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER].
Shouval R; Livneh A; Ben-Zvi I
Harefuah; 2015 Nov; 154(11):716-9, 741. PubMed ID: 26821505
[TBL] [Abstract][Full Text] [Related]
24. Investigation of the arterial stiffness and associated factors in patients with familial Mediterranean fever.
Çakar M; Akhan M; Doğan T; Taşkın G; Öztürk K; Çınar M; Arslan E; Yılmaz S
Anatol J Cardiol; 2017 Feb; 17(2):132-138. PubMed ID: 27488756
[TBL] [Abstract][Full Text] [Related]
25. Update on the management of colchicine resistant Familial Mediterranean Fever (FMF).
El Hasbani G; Jawad A; Uthman I
Orphanet J Rare Dis; 2019 Oct; 14(1):224. PubMed ID: 31615541
[TBL] [Abstract][Full Text] [Related]
26. Colchicine-induced myopathy in a teenager with familial Mediterranean fever.
Sayarlioglu M; Sayarlioglu H; Ozen S; Erkoc R; Gul A
Ann Pharmacother; 2003 Dec; 37(12):1821-4. PubMed ID: 14632592
[TBL] [Abstract][Full Text] [Related]
27. Arterial Stiffness and Ambulatory Blood Pressure Measurements in Children With Familial Mediterranean Fever.
Leventoğlu E; Büyükkaragöz B; Sunar Yayla EN; Esmeray Şenol P; Bakkaloğlu SA
Clin Pediatr (Phila); 2023 Nov; ():99228231211705. PubMed ID: 37937548
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of treatments in Familial Mediterranean fever: a systematic review.
Demirkaya E; Erer B; Ozen S; Ben-Chetrit E
Rheumatol Int; 2016 Mar; 36(3):325-31. PubMed ID: 26687683
[TBL] [Abstract][Full Text] [Related]
29. Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment.
Bilgen SA; Kilic L; Akdogan A; Kiraz S; Kalyoncu U; Karadag O; Ertenli I; Dogan I; Calguneri M
J Clin Rheumatol; 2011 Oct; 17(7):358-62. PubMed ID: 21946459
[TBL] [Abstract][Full Text] [Related]
30. [Familial Mediterranean Fever (FMF): from diagnosis to treatment].
Medlej-Hashim M; Loiselet J; Lefranc G; Mégarbané A
Sante; 2004; 14(4):261-6. PubMed ID: 15745878
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of various cardiac autonomic indices in patients with familial Mediterranean fever on colchicine treatment.
Canpolat U; Dural M; Aytemir K; Akdoğan A; Kaya EB; Sahiner L; Yalçin U; Canpolat AG; Calgüneri M; Kabakçi G; Tokgözoğlu L; Oto A
Auton Neurosci; 2012 Apr; 167(1-2):70-4. PubMed ID: 22104493
[TBL] [Abstract][Full Text] [Related]
32. The anemia of familial Mediterranean fever disease.
Celkan T; Celik M; Kasapçopur O; Ozkan A; Apak H; Ocak S; Arisoy N; Yildiz I
Pediatr Hematol Oncol; 2005 Dec; 22(8):657-65. PubMed ID: 16251171
[TBL] [Abstract][Full Text] [Related]
33. Association between familial mediterranean fever and retroperitoneal fibrosis: retroperitoneal fibrosis regression after colchicine therapy.
De Socio G; Cerquaglia C; Curigliano V; Fonnesu C; Giovinale M; Verrecchia E; Marino GM; Natale L; Gasbarrini GB; Manna R
Int J Immunopathol Pharmacol; 2009; 22(2):521-4. PubMed ID: 19505404
[TBL] [Abstract][Full Text] [Related]
34. Colchicine therapy and the cognitive status of elderly patients with familial Mediterranean fever.
Leibovitz A; Lidar M; Baumoehl Y; Livneh A; Segal R
Isr Med Assoc J; 2006 Jul; 8(7):469-72. PubMed ID: 16889161
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of ischemic heart disease in patients with familial Mediterranean fever.
Langevitz P; Livneh A; Neumann L; Buskila D; Shemer J; Amolsky D; Pras M
Isr Med Assoc J; 2001 Jan; 3(1):9-12. PubMed ID: 11344818
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for amyloidosis and impact of kidney transplantation on the course of familial Mediterranean fever.
Ben-Zvi I; Danilesko I; Yahalom G; Kukuy O; Rahamimov R; Livneh A; Kivity S
Isr Med Assoc J; 2012 Apr; 14(4):221-4. PubMed ID: 22675837
[TBL] [Abstract][Full Text] [Related]
37. Colchicine intoxication in familial Mediterranean fever patients using clarithromycin for the treatment of Helicobacter pylori: a series of six patients.
Haj Yahia S; Ben Zvi I; Livneh A
Rheumatol Int; 2018 Jan; 38(1):141-147. PubMed ID: 28975396
[TBL] [Abstract][Full Text] [Related]
38. Is there a relationship between serum omentin level and acute phase response in patients with familial Mediterranean fever?
Can Sandikci S; Omma A; Yucel C; Omma T
Clin Rheumatol; 2021 Feb; 40(2):669-674. PubMed ID: 32623649
[TBL] [Abstract][Full Text] [Related]
39. An evaluation with shear wave elastography of kidney elasticity in patients with familial Mediterranean fever.
Kayalı A; Öztürk Keleş F; Seyfettin A; Dirican E; Çelik MM
J Clin Ultrasound; 2023 Jan; 51(1):177-183. PubMed ID: 36251543
[TBL] [Abstract][Full Text] [Related]
40. Corneal wound healing in a patient treated with colchicine for familial Mediterranean Fever (FMF).
Leibovitch I; Alster Y; Lazar M; Langevitz P; Livneh A; Loewenstein A
Rheumatology (Oxford); 2003 Aug; 42(8):1021-2. PubMed ID: 12869680
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
